71 – 80 of 256
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
A Prognostic Index Composed of Progesterone Receptor Status, Tumour Size and S-phase Fraction, Predicts Survival in Node-Negative Breast Cancer Patients in a Large Multicentre Prospective Cohort Study.
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial
(
- Contribution to journal › Article
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
-
Mark
The Prognostic Value of Mitotic Activity Index (MAI), Phosphohistone H3 (PPH3), Cyclin B1, Cyclin A, and Ki67, Alone and in Combinations, in Node-Negative Premenopausal Breast Cancer.
(
- Contribution to journal › Article
-
Mark
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
(
- Contribution to journal › Article
-
Mark
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
(
- Contribution to journal › Article
-
Mark
Toward a Molecular Pathologic Classification of Urothelial Carcinoma.
(
- Contribution to journal › Article
-
Mark
The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
(
- Contribution to journal › Article
-
Mark
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor.
(
- Contribution to journal › Article
-
Mark
Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution.
(
- Contribution to journal › Article